EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats

Stijn J M Niessen iD, Hans S Kooistra, Yaiza Forcada, Charlotte R Bjørnvad iD, Balazs Albrecht iD, Franziska Roessner, Esther Herberich, Carla Kroh

Journal of Veterinary Internal Medicine · 01.07.2024 · 38 (4) · 2099-2119

DOI: 10.1111/jvim.17124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, online erschienen am 01.07.2024. Verfasst von Stijn J M Niessen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Veterinary Specialist Consultations & VIN Europe, Hilversum, The Netherlands. Hauptthemen laut MEDLINE: Cat Diseases, Hypoglycemic Agents, Insulin, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim Animal Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Options for treatment of diabetes mellitus in cats are limited to insulin injections and monitoring for hypoglycemia. Hypothesis Once daily sodium-glucose cotransporter-2 inhibitor velagliflozin PO is noninferior to insulin injections. Animals Client-owned diabetic cats (127 safety; 116 efficacy assessment).

Methods

Prospective, randomized (1 mg/kg velagliflozin), positive controlled (titrated Caninsulin), open label, noninferiority field trial, comparing number of cats with treatment success in ≥1 clinical variable and ≥1 glycemic variable (margin Δ: 15%) on Day 45; secondary endpoints included glycemic and clinical assessments during 91 days.

Results

On Day 45, 29/54 (54%) velagliflozin-treated cats and 26/62 (42%) Caninsulin-treated cats showed treatment success, demonstrating noninferiority (difference −11.8%; upper 1-sided 97.5% confidence interval, −∞ to 6.3%). By Day 91, quality of life (QoL), polyuria, and polydipsia had improved in 81%, 54% and 61% (velagliflozin); on blood glucose (BG) curves, mean BG was <252 mg/dL in 42/54 (78%; velagliflozin) and 37/62 (60%; Caninsulin); minimum BG was <162 mg/dL in 41/54 (76%; velagliflozin) and 41/62 (66%; Caninsulin); serum fructosamine was <450 μmol/L in 41/54 (76%; velagliflozin) and 38/62 (61%; Caninsulin). Velagliflozin's most frequent adverse events were loose feces/diarrhea (n = 23/61, 38%), positive urine culture (n = 19/61, 31%), and nonclinical hypoglycemia (BG <63 mg/dL; n = 8/61, 13%); Caninsulin's: clinical and nonclinical hypoglycemia (n = 35/66, 53%), positive urine culture (n = 18/66, 27%), and loose feces/diarrhea (n = 10/66, 15%). Diabetic ketoacidosis occurred in 4/61 (7%; velagliflozin) and 0/66 (Caninsulin). Conclusions and Clinical Importance Once daily oral administration of velagliflozin was noninferior to insulin injections, showed good QoL and glycemia without clinical hypoglycemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cat DiseasesHypoglycemic AgentsInsulinSodium-Glucose Transporter 2 InhibitorsAnimalsCatsFemaleMaleAdministration, OralBlood GlucoseDiabetes MellitusDrug Administration ScheduleProspective Studies

Stichwörter der Autor:innen

antidiabeticbeta‐cellcompliancefeline diabetes mellitusglucosuriaglucotoxicityglycemic controlprospective clinical trialsodium‐glucose cotransporter‐2 (SGLT2) inhibitor

Substanzen

Blood GlucoseHypoglycemic AgentsInsulinSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Veterinary Specialist Consultations & VIN Europe, Hilversum, The Netherlands.
  • Royal Veterinary College, University of London, Hertfordshire, United Kingdom.
  • Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
  • Bjørnvad Consultancy, Vedbæk, Denmark.
  • Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany.

ORCID-Profile: Stijn J M Niessen, Charlotte R Bjørnvad, Balazs Albrecht

Förderung

  • Boehringer Ingelheim Animal Health

Zitieren

APA

Niessen, S. J. M., Kooistra, H. S., Forcada, Y., Bjørnvad, C. R., Albrecht, B., Roessner, F., Herberich, E., & Kroh, C. (2024). Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats. Journal of Veterinary Internal Medicine, 38(4), 2099-2119. https://doi.org/10.1111/jvim.17124

Vancouver

Niessen SJM, Kooistra HS, Forcada Y, Bjørnvad CR, Albrecht B, Roessner F, et al. Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats. Journal of Veterinary Internal Medicine. 2024;38(4):2099-2119. doi:10.1111/jvim.17124

BibTeX
@article{Niessen2024,
  author = {Niessen, Stijn J M and Kooistra, Hans S and Forcada, Yaiza and Bjørnvad, Charlotte R and Albrecht, Balazs and Roessner, Franziska and Herberich, Esther and Kroh, Carla},
  title = {Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2024},
  volume = {38},
  number = {4},
  pages = {2099--2119},
  doi = {10.1111/jvim.17124}
}
Kostenlos starten →